Cytokinetics Inc (CYTK) — SEC Filings
Cytokinetics Inc (CYTK) — 49 SEC filings. Latest: 8-K (Dec 19, 2025). Includes 28 8-K, 10 SC 13G/A, 5 10-Q.
View Cytokinetics Inc on SEC EDGAR
Overview
Cytokinetics Inc (CYTK) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 19, 2025: Cytokinetics, Incorporated filed an 8-K on December 19, 2025, reporting an event under 'Other Events'. The filing does not contain specific details about the event itself, but confirms the company's principal executive offices are located at 350 Oyster Point Boulevard, South San Francisco, Californi
Sentiment Summary
Across 49 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 46 neutral. The dominant filing sentiment for Cytokinetics Inc is neutral.
Filing Type Overview
Cytokinetics Inc (CYTK) has filed 28 8-K, 5 10-Q, 1 8-K/A, 2 DEF 14A, 2 10-K, 1 SC 13G, 10 SC 13G/A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (49)
Risk Profile
Risk Assessment: Of CYTK's 37 recent filings, 1 were flagged as high-risk, 15 as medium-risk, and 21 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $70.284M |
| Net Income | -$306.178M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $225.467M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | $1.957B |
Key Executives
- Dr. Fady Malik
- Ms. Lori Wood
- Dr. Andrew W. Lo
- Ms. Michelle L. Griffin
- Robert Iannone
- Robert J. Alexander
- Dr. Andrew Schwab
- Ms. Sarah Kelly
- Mr. Robert J. Hanna
- Dr. Robert E. Conway
- Ms. Mary Ann L. Lammie
- Robert I. Blum
- Robert A. Harrington
- John O. Faurescu
- Abigail P. Johnson
Industry Context
Cytokinetics operates in the highly competitive and capital-intensive biotechnology sector, focusing on the development of novel therapeutics for cardiovascular and other diseases. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success hinges on innovation, clinical trial efficacy, and securing adequate funding to advance pipeline candidates through development and commercialization.
Top Tags
regulatory-filing (6) · amendment (5) · 8-k (5) · executive-compensation (5) · 8-K (4) · 10-Q (4) · governance (4) · institutional-ownership (4) · disclosure (3) · financials (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $306.178M | Increased from $160.545M in Q3 2024, primarily due to debt conversion expense. |
| Debt Conversion Expense | $121.249M | Significant one-time expense impacting Q3 2025 net loss. |
| Total Revenues (9 months) | $70.284M | Substantial increase from $1.547M in 9 months 2024, driven by license and milestone revenues. |
| License and Milestone Revenues (9 months) | $64.353M | Key driver of revenue growth for the nine-month period. |
| Research and Development Expenses (9 months) | $311.628M | Increased from $245.779M in 9 months 2024, reflecting ongoing pipeline investment. |
| Cash and Cash Equivalents | $225.467M | As of September 30, 2025, up from $94.857M at December 31, 2024. |
| Convertible Notes, net | $889.524M | Increased from $552.370M at December 31, 2024, contributing to higher liabilities. |
| Liabilities related to revenue participation right purchase agreements, net | $504.498M | Increased from $462.192M at December 31, 2024. |
| Total Stockholders' Deficit | $521.123M | Increased from $135.372M at December 31, 2024, indicating worsening financial position. |
| Common Stock Outstanding | 122,264,929 | As of November 3, 2025, indicating potential dilution from prior periods. |
| Reporting Period End Date | 20250331 | Quarterly financial reporting |
| Filing Date | 20250506 | Date the 10-Q was submitted to the SEC |
| SEC File Number | 000-50633 | Identifies the specific SEC filing for Cytokinetics. |
| Film Number | 25826496 | Internal SEC processing number for the filing. |
| Fiscal Year End | 20241231 | Reporting period for the 10-K filing. |
Forward-Looking Statements
- {"claim":"FMR LLC will maintain a significant, passive stake in Cytokinetics Inc. for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
- {"claim":"Wellington Management Group LLP will maintain a significant, albeit potentially adjusted, stake in Cytokinetics, Incorporated.","entity":"Wellington Management Group LLP","targetDate":"next 6-12 months","confidence":"medium"}
- {"claim":"Cytokinetics, Incorporated's stock will continue to be influenced by institutional investor activity.","entity":"Cytokinetics, Incorporated","targetDate":"next 3-6 months","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Cytokinetics Inc (CYTK)?
Cytokinetics Inc has 49 recent SEC filings from Jan 2024 to Dec 2025, including 28 8-K, 10 SC 13G/A, 5 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CYTK filings?
Across 49 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 46 neutral. The dominant sentiment is neutral.
Where can I find Cytokinetics Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Cytokinetics Inc (CYTK) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Cytokinetics Inc?
Key financial highlights from Cytokinetics Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CYTK?
The investment thesis for CYTK includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Cytokinetics Inc?
Key executives identified across Cytokinetics Inc's filings include Dr. Fady Malik, Ms. Lori Wood, Dr. Andrew W. Lo, Ms. Michelle L. Griffin, Robert Iannone and 10 others.
What are the main risk factors for Cytokinetics Inc stock?
Of CYTK's 37 assessed filings, 1 were flagged high-risk, 15 medium-risk, and 21 low-risk.
What are recent predictions and forward guidance from Cytokinetics Inc?
Recent forward-looking statements from Cytokinetics Inc include guidance on {"claim":"FMR LLC will maintain a significant, passive stake in Cytokinetics Inc. for the foreseeable future.","entity": and 2 other predictions.